Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen E/I Balance in ASD
NCT03594552Completed
- Sponsor
- King's College London
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of arbaclofen in Autism Spectrum Disorder (ASD) (6 arms), sponsored by King's College London. Primary endpoint: Neurochemical response to GABAergic stimulation. Started Feb 2018; status: completed.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03594552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594552.